Dana-Farber Cancer Institute — Biomedical Watch V2

Traitements6programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

6

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
Excision of tumor/mastectomyThis research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2. The names of the study interventions involved in this study are: * Trastuzumab emtansine (also called T-DM1) * Pertuzumab	Cancer	Phase 2	À vérifier	United States	À vérifier
PertuzumabThis research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2. The names of the study interventions involved in this study are: * Trastuzumab emtansine (also called T-DM1) * Pertuzumab	Cancer	Phase 2	À vérifier	United States	À vérifier
PF04518600This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma. The drugs involved are: * Rituximab * Utomilumab * Avelumab * PF-04518600	SEP	Phase 1	À vérifier	United States	À vérifier
T-DM1This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2. The names of the study interventions involved in this study are: * Trastuzumab emtansine (also called T-DM1) * Pertuzumab	Cancer	Phase 2	À vérifier	United States	À vérifier
UtomilumabThis research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma. The drugs involved are: * Rituximab * Utomilumab * Avelumab * PF-04518600	SEP	Phase 1	À vérifier	United States	À vérifier
T-DM1This research study is studying a combination of drugs as a possible treatment for breast cancer that has tested positive for a protein called HER2. The names of the study interventions involved in this study are: * Trastuzumab emtansine (also called T-DM1) * Pertuzumab	Cancer	Phase 2	À vérifier	United States	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
T-DM1	Cancer	Phase 2	NCT02326974	T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA	ACTIVE_NOT_RECRUITING
Rituximab	SEP	Phase 1	NCT03636503	Rituximab + Immunotherapy in Follicular Lymphoma	TERMINATED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.